Sign in to view content

Pharmacokinetic Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 3 Archway Trial

Peter A. Campochiaro, MD

Video
Published 2021

Related

Are There Safety Concerns With Bevacizumab for ROP
Robert L. Avery, MD
Updates from the Field
2017
Dual Targeting VEGF/Ang3 Surrobody in an Experimental Model of Neovascularization
Jeffrey L. Olson, MD
Annual Meeting Talks
2019
Episode 147: CEP290 mRNA intravitreal therapy for LCA
Jayanth Sridhar, MD
Member Podcasts
2018

Category: Pharmacology

See more